[{"id":"1eeb0f08-7927-4438-a063-9e9859dc3e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516289","created_at":"2025-02-26T10:01:45.127Z","updated_at":"2025-02-26T10:01:45.127Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab","source_id_and_acronym":"NCT06516289","lead_sponsor":"Fudan University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"d985b472-e638-4ad1-93ec-e5ff886eaca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05473624","created_at":"2022-07-26T17:09:56.344Z","updated_at":"2024-07-02T16:35:35.416Z","phase":"Phase 1","brief_title":"Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05473624","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-28"}]